Skip to main content

Table 2 Changes in estrogen receptor, progesterone receptor, and HER2 receptors

From: Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)

Receptor status of primary

Number

(Percentage)

Allred status of recurrence

Number

(Percentage)

Quickscore status of recurrence

Number

(Percentage)

ER+

109

(79.6%)

ER+

98

(71.5%)

ER+

100

(73.0%)

  

ER-

11

(8.0%)

ER-

9

(6.6%)

ER-

28

(20.4%)

ER-

25

(18.2%)

ER-

24

(17.5%)

  

ER+

3

(2.2%)

ER+

4

(2.9%)

PR+

85

(62.0%)

PR+

63

(46.0%)

PR+

53

(38.7%)

  

PR-

22

(16.0%)

PR-

32

(23.4%)

PR-

52

(38%)

PR-

40

(29.2%)

PR-

40

(29.2%)

  

PR+

12

(8.8%)

PR+

12

(8.8%)

  

HER2 status of recurrence

Number

(Percentage)

  

HER2+

14

(10.2%)

HER2+

13

(9.5%)

  
  

HER2-

1

(0.7%)

  

HER2-

123

(89.8%)

HER2-

120

(87.6%)

  
  

HER2+

3

(2.2%)

  
  1. ER, estrogen receptor; HER2, human epidermal growth factor type 2; PR, progesterone receptor.